Drug Profile
Imiglucerase biosimilar - Dong-A ST
Alternative Names: DA 3811; Glucosylceramidase analogue - Dong-A Pharmaceutical; β-glucoerebrosidase analogue - Dong-A PharmaceuticalLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Dong-A Pharmaceutical
- Developer Dong-A ST
- Class Enzymes; Glucosidases; Peptidomimetics
- Mechanism of Action Glucosylceramidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Gaucher's disease
Highest Development Phases
- No development reported Gaucher's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Gaucher's-disease in South Korea (IV, Injection)
- 30 Sep 2013 Phase-I clinical trials in Gaucher's disease in South Korea (IV)